A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma

Lori Alexander

doi:10.1177/155989770700700305

Lori Alexander

Institut Gustave Roussy, Paris, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
View author's works on this site

Bernard Escudier

Institut Gustave Roussy, Paris, France

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
View author's works on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF

Article Figures & Data

Tables

Download powerpoint

PreviousNext

Tools

Download PDF

View Full Page PDF

Citation Tools

A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Thank you for your interest in spreading the word on MD Conference Express.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma

Message Subject (Your Name) has sent you a message from MD Conference Express

Message Body (Your Name) thought you would like to see the MD Conference Express web site.

Your Personal Message

A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma

Permalink: Copy

Linkedin Share Button